UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2021
Commission File No. 001-39530
ImmunoPrecise Antibodies Ltd.
(Translation of registrant’s name into English)
3204-4464 Markham Street Victoria, British Columbian V8Z 7X8
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☐ Form 40-F ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7): ☐
INCORPORATION BY REFERENCE
Exhibit 99.2 of this Form 6-K is incorporated by reference into the Registration Statement on Form F-10 (File No. 333-249957) and Registration Statement on Form S-8 (File No. 333-256730) of the Registrant, Immunoprecise Antibodies Ltd.
EXHIBIT INDEX
Exhibit | Description | |
99.1 | News release dated October 13, 2021 | |
99.2 | At-The-Market Offering Agreement by and between Immunoprecise Antibodies Ltd. and H.C. Wainwright & Co., LLC, dated October 13, 2021 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
IMMUNOPRECISE ANTIBODIES LTD. | ||||||
Date: October 13, 2021 | ||||||
By: | /s/ Lisa Helbling | |||||
Name: | Lisa Helbling | |||||
Title: | Chief Financial Officer |
2